PUBLISHER: Grand View Research | PRODUCT CODE: 2067521
PUBLISHER: Grand View Research | PRODUCT CODE: 2067521
The global biologics contract research organizations market size was estimated at USD 14.88 billion in 2025 and is projected to reach USD 32.30 billion by 2033, growing at a CAGR of 10.3% from 2026 to 2033. The market growth is driven by rising demand for biologics, increasing outsourcing trends among pharmaceutical companies, growing requirements for personalized medicine, and cell & gene therapies.
In addition, rising technological advancements in clinical trial management and stringent regulatory requirements that underscore the need for specialized CRO expertise among biopharmaceutical companies are expected to drive the market. In the global biologics contract research organizations (CRO) market, the CRO are experiencing growing demand for biologics, including monoclonal antibodies, vaccines, and cell & gene therapies. Most of these complex molecules require specialized research, clinical trials, and regulatory expertise that many pharmaceutical companies lack in-house. Thus, these factors have led to a growing need for CRO services, as they offer biologics-focused trial design, bioanalytical testing, and manufacturing support, further accelerating development timelines, reducing costs, and ensuring high-quality data, making them indispensable partners for sponsors navigating the expanding biologics pipeline. This trend is emerging in the therapies, where CROs' specialized knowledge and infrastructure are critical for successful clinical outcomes.
In addition, increasing adoption of artificial intelligence (AI) and machine learning (ML) in drug development is driving efficiency gains across biologics CRO operations. AI-enabled tools are improving clinical trial design, patient monitoring, regulatory documentation, and data management, reducing cycle times by approximately 18% on average. Moreover, time savings in patient monitoring and in regulatory documentation processes are enhancing trial execution efficiency. In addition, regulatory support for AI integration, particularly in biologics submissions, is accelerating adoption across CROs. Furthermore, rising investment in AI-enabled platforms is enabling faster decision-making, optimized resource utilization, and improved trial outcomes, thereby increasing outsourcing demand for advanced biologics CRO services.
Moreover, other factors contributing to market growth include rising technological advancements in clinical trial management, which are transforming the operations within biologics CROs. Integrating AI, machine learning, and data analytics further enables faster patient recruitment, predictive modeling, and real-time monitoring of clinical trial data. Furthermore, digital platforms, electronic data capture (EDC), and decentralized trial solutions further enhance efficiency, transparency, and compliance, which are expected to drive market growth. Automation and advanced bioinformatics further streamline data handling for complex biologics studies. These technologies support reducing errors, improving decision-making, and accelerating trial timelines. Thus, as biological research becomes increasingly data-intensive, most CROs opt for technology-driven solutions to manage complexity, optimize trial outcomes, and support sponsors in bringing innovative therapies to market faster.
Global Biologics Contract Research Organizations Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biologics contract research organizations market based on type, product, service, therapeutic area, end use, and region.